CN116744970A - 包含sfrp2拮抗剂的组合物和方法 - Google Patents

包含sfrp2拮抗剂的组合物和方法 Download PDF

Info

Publication number
CN116744970A
CN116744970A CN202180090221.0A CN202180090221A CN116744970A CN 116744970 A CN116744970 A CN 116744970A CN 202180090221 A CN202180090221 A CN 202180090221A CN 116744970 A CN116744970 A CN 116744970A
Authority
CN
China
Prior art keywords
antigen
sfrp2
antibody
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090221.0A
Other languages
English (en)
Chinese (zh)
Inventor
N·德摩尔
C·帕特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN116744970A publication Critical patent/CN116744970A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180090221.0A 2020-12-11 2021-12-10 包含sfrp2拮抗剂的组合物和方法 Pending CN116744970A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124345P 2020-12-11 2020-12-11
US63/124,345 2020-12-11
PCT/US2021/062854 WO2022125927A1 (en) 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists

Publications (1)

Publication Number Publication Date
CN116744970A true CN116744970A (zh) 2023-09-12

Family

ID=81974701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090221.0A Pending CN116744970A (zh) 2020-12-11 2021-12-10 包含sfrp2拮抗剂的组合物和方法

Country Status (10)

Country Link
US (2) US11873333B2 (https=)
EP (1) EP4259203A4 (https=)
JP (1) JP7747350B2 (https=)
KR (1) KR102934264B1 (https=)
CN (1) CN116744970A (https=)
AU (1) AU2021396381A1 (https=)
CA (1) CA3201893A1 (https=)
IL (1) IL303600A (https=)
MX (1) MX2023006777A (https=)
WO (1) WO2022125927A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법
WO2025076318A1 (en) * 2023-10-06 2025-04-10 Musc Foundation For Research Development Compositions for modulating the kras pathway and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2015038882A1 (en) * 2013-09-13 2015-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy
KR102934264B1 (ko) 2020-12-11 2026-03-05 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Sfrp2 길항제를 포함하는 조성물 및 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Also Published As

Publication number Publication date
KR20230118904A (ko) 2023-08-14
US12258388B2 (en) 2025-03-25
US11873333B2 (en) 2024-01-16
US20220204598A1 (en) 2022-06-30
IL303600A (en) 2023-08-01
WO2022125927A1 (en) 2022-06-16
CA3201893A1 (en) 2022-06-16
EP4259203A1 (en) 2023-10-18
EP4259203A4 (en) 2024-12-18
KR102934264B1 (ko) 2026-03-05
JP2023553938A (ja) 2023-12-26
JP7747350B2 (ja) 2025-10-01
US20240190949A1 (en) 2024-06-13
AU2021396381A1 (en) 2023-07-06
MX2023006777A (es) 2023-08-17

Similar Documents

Publication Publication Date Title
CN111433223B (zh) 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
DK2646470T3 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
KR101320198B1 (ko) 신생물의 치료를 위한 조성물 및 방법
KR102934264B1 (ko) Sfrp2 길항제를 포함하는 조성물 및 방법
KR102478986B1 (ko) 암 치료용 항-ck8 항체
CN113260385B (zh) 抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
JP2024026138A (ja) プラチナベースの薬剤と抗組織因子抗体－薬物コンジュゲートの組み合わせを用いるがんの治療方法
CN113166242B (zh) 用于癌症的组合疗法
KR102863169B1 (ko) B7-h4 항체 투약 섭생법
KR20200040881A (ko) 항-pacap 항체
CN116322787A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
ES2865303T3 (es) Ligante de adrenomedulina para su uso en la terapia del cáncer
KR20230109854A (ko) 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도
CN114845738A (zh) 使用位点特异性her2抗体-药物缀合物的治疗
HK40068969A (en) Treatment with site specific her2 antibody-drug conjugates
HK40057716B (zh) 用於癌症的组合疗法
HK40057716A (en) Combination therapy for cancer
HK40036127B (zh) B7-h4抗体给药方案
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
HK40036127A (en) B7-h4 antibody dosing regimens
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination